NCT03802591 - A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | Biotech Hunter

Enrollment

479

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

July 9, 2023

Study Completion Date

September 22, 2023

Conditions

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

CS1001 monoclonal antibody

Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months

DRUG

CS1001 placebo

Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months

DRUG

Oxaliplatin

Administered as an IV infusion on Day 1 Q3W

DRUG

Capecitabine

Administered by oral, twice a day on Day 1 - Day 14 of each cycle.

Trial Locations (1)

Beijing Cancer Hospital, Beijing